SCHEMBL20394199

SCHEMBL20394199

COc1ccccc1-c1ccc(C)nc1Oc1ccc(C(F)(F)F)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 4/20 0.41
HTT P42858 3/20 0.41
TSHR P16473 3/20 0.41
PTGS2 P35354 1/20 0.40
HPGD P15428 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 3/20 0.38
MITF O75030 1/20 0.38
STAT3 P40763 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KMT2A Q03164 2/20 0.36
PPP1CA P62136 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18661517 0.85 PDE10A (0.46) ALDH1A1SMN1; SMN2L3MBTL1LMNAKMT2A
SCHEMBL20394397 0.84 GPBAR1 (0.40) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL20394444 0.82 KDM4E (0.38) KDM4EMAPTALDH1A1HSD17B10HTT
SCHEMBL20394149 0.82 PDE10A (0.40) KDM4EMAPTALDH1A1SMN1; SMN2HSD17B10
SCHEMBL18661341 0.81 CYP3A4 (0.47) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL18661511 0.80 GPBAR1 (0.41) L3MBTL1PDE10ACYP1A2CYP2C9CYP2C19
SCHEMBL20394296 0.79 KMT2A (0.40) KDM4EMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL20394376 0.79 DRD1 (0.38) KDM4EMAPTALDH1A1HTTPTGS2
SCHEMBL18661516 0.77 PDE10A (0.45) ALDH1A1SMN1; SMN2L3MBTL1LMNAKMT2A
SCHEMBL20406571 0.76 PDE10A (0.38) KDM4EMAPTALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA KDM4E 2642/4885MAPT 4703/4885ALDH1A1 2994/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA KDM4E 2642/4885MAPT 4703/4885ALDH1A1 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.